prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, Clinical Diagnosis & History: 1.2. cm invasive duct carcinoma left breast upper outer quadrant (on core. biopsy) for left wide excision SLNB, possible left ALND. Specimens Submitted: 1: SP: Sentinel node #1 level one left axilla (fs). 2: SP: Sentinel node #2 level one left axilla (fs). 3: SP: Excision of tumor left breast two o'clock. 4: SP: Superior margin left breast. 5: SP: Medial margin left breast. 6: SP: Inferior margin left breast. 7: SP: Lateral margin left breast. 8: SP: Non-sentinel node left axilla. 9: SP: Posterior margin left breast. 10: SP: Levels one and two left axillary contents. DIAGNOSIS: 1. LYMPH NODE, SENTINEL #1, LEVEL I, LEFT AXILLA; EXCISION: - METASTATIC ADENOCARCINOMA IN ONE LYMPH NODE (1/1). THE METASTATIC FOCUS MEASURES 5 MM IN GREATEST DIMENSION. - NEGATIVE FOR EXTRACAPSULAR EXTENSION. 2. LYMPH NODE, SENTINEL #2 LEVEL I LEFT AXILLA; EXCISION: METASTATIC ADENOCARCINOMA IN ONE LYMPH NODE (1/1). THE METASTATIC FOCUS MEASURES 6 MM IN GREATEST DIMENSION. - EXTRACAPSULAR EXTENSION (>2MM) IS PRESENT. 3. BREAST, LEFT, 2 O'CLOCK; EXCISION: - INVASIVE DUCTAL CARCINOMA, NOS TYPE, HISTOLOGIC GRADE II/III. (MODERATE TUBULE FORMATION), NUCLEAR GRADE I/III (SLIGHT OR NO VARIATION IN. SIZE AND SHAPE), MEASURING 2.0 CM IN LARGEST DIMENSION MICROSCOPICALLY. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID TYPE WITH LOW TO. INTERMEDIATE NUCLEAR GRADE. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR MASS,. AND IS PRESENT ADMIXED WITH THE INVASIVE COMPONENT. - CALCIFICATIONS ARE PRESENT IN THE INVASIVE CARCINOMA ONLY. FOCAL VASCULAR INVASION IS PRESENT. FOR SURGICAL MARGINS SEE PARTS 4-7, AND 9. THE NON-NEOPLASTIC BREAST TISSUE THE NON-NEOPLASTIC BREAST TISSUE. SHOWS BIOPSY SITE CHANGES. RESULTS OF 108, PR, HER2-NEU) ARE AS FOLLOWS: ESTROGEN RECEPTOR. 95% nuclear staining with inhensity. PROGESTERONE RECEPTOR. 70% nucl. ith moderate intensity. HER2. Negative (1+). (<5% of invasive tumor cells exhibit weak complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pattern: absent). Comment: Controls are satisfactory. PATHWAY anti-HER-2/neu is an. FDA-approved rabbit monoclonal primary antibody (clone 485) directed against. the internal domain of the c-erbB-2 oncoprotein (HER2) for. immunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation. The HER2 test. results are reported in accordance with the ASCO/CAP guideline. recommendations for HER2 testing in breast cancer (J Clin Oncol 2007;. 25 (1) :118-145) The ER and PR rabbit monoclonal antibodies are also FDA. approved. 4. BREAST, LEFT, SUPERIOR MARGIN; EXCISION: - BENIGN BREAST TISSUE WITH PROLIFERATIVE FIBROCYSTIC CHANGES. 5. BREAST, LEFT, MEDIAL MARGIN; EXCISION: BENIGN BREAST TISSUE WITH FOCAL USUAL DUCTAL HYPERPLASIA. 6. BREAST, LEFT, INFERIOR MARGIN; EXCISION: - BENIGN BREAST TISSUE WITH FOCAL USUAL DUCTAL HYPERPLASIA. 7. BREAST, LEFT, LATERAL MARGIN; EXCISION: - BENIGN BREAST TISSUE WITH FOCAL USUAL DUCTAL HYPERPLASIA. LYMPH NODE, NON-SENTINEL, LEFT AXILLA; EXCISION: - ONE BENIGN LYMPH NODK (0/1). 9. BREAST, LEFT, POSTERIOR MARGIN; EXCISION: BENIGN BREAST TISSUE PREDOMINANTLY COMPOSED OF FIBROADIPOSK. ELEMENTS. SKELETAL MUSCLE TISSUE ALSO PRESENT. 10. LYMPH NODES, LEFT AXILLARY CONTENTS, LEVELS ONE AND TWO, EXCISION: ELEVEN BENIGN LYMPH NODES (0/11). Some of the mmunohistochemistry and. :ests were developed and their. performance characteristics were determined by. They have not been cleared or approved by the US FOO ana urug. Administration. The FDA has determined that such clearance or approval is. not necessary. These tests are used for clinical purposes. They should not. be regarded as investigational or for research. This laboratory is certified. under the Clinical Laboratory Improvement Amendments of 1988 (CLIA , 88) as. qualified to perform high complexity clinical laboratory testing. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES - (AND/OR OTHER MATERIAL) . AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: 1. 1) The specimen is received fresh for frozen labeled, "Sentinel node #1,. level 1, left axilla", and consists of one fatty lymph node measuring 2.5 x. 1.5 x 1.5 cm, which is trisected and representatively submitted. A portion. of tissue sent to TPS. The remaining lymph node is submitted to permanent. Summary of sections: fac -- lymph node frozen section control. RS- remaining lymph node. 2) The specimen is received fresh for frozen labeled, "Sentinel node #2,. level 1, left axilla", and consists of one fatty lymph node measuring 2.4 x. 1.5 x 1.2 cm, which is trisected and representatively submitted. A portion. of tissue sent to TPS. The remaining lymph node is submitted to permanent. Summary of sections: fsc -- lymph node frozen section control. RS- remaining lymph node. 3) The specimen is received unoriented and fresh, labeled "excision of. tumor, left breast two o' clock" and consists of a piece of fibrofatty. breast tissue measuring 5.2 x 5.0 x 2.3 cm. The specimen is entirely inked. black. Serial sectioning reveals a spiculated, white mass measuring 1.2 x. 1.2 x 1.1 cm. Sectioning through the remaining breast tissue reveals yellow. adipose tissue. A clip is identified. The tumor is entirely submitted and. the remaining tissue is representatively submitted and a small portion is. given to TPS. Summary of sections: MT - tumor and closest tissue edge. T - tumor (clip was in block 2). SS - serial sections remaining tissue. 4) The specimen is received fresh, labeled "superior margin left breast" and. consists of a piece of fibrofatty breast tissue measuring 5.0 x 3.0 cm, and. 1.3 cm thick. A stitch marks the new margin of excision, which is inked. black. The tissue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 5) The specimen is received fresh, labeled "medial margin left breast" and. consists of a piece of fibrofatty breast tissue measuring 3.2 x 2.5 cm, and. 1.2 cm thick. A stitch marks the new margin of excision, which is inked. black. The tissue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 6) The specimen is received fresh, labeled inferior margin left breast" and. consists of a piece of fibrofatty breast tissue measuring 4.0 x 3.0 cm, and. 1.3 cm thick. A stitch marks the new margin of excision, which is inked. black. The tiasue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 7) The specimen is received fresh, labeled "lateral margin left breast" and. consists of a piece of fibrofatty breast tissue measuring 4.4 x 2.8 cm, and. 1.2 cm thick. A stitch marks the new margin of excision, which is inked. black. The tiasue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 8) The specimen is received in formalin, labeled "Non-sentinel node left. axilla" and consists of a single pink tan fatty lymph node measuring 0.9 cm. The lymph node is bisected and entirely submitted. Summary of sections: BLN-bisected lymph node. 9). The specimen is received fresh, labeled "posterior margin, left breast". and consists of a piece of fibrofatty breast tissue measuring 4.2 x 3.0 cm,. and 0.5 cm thick. The specimen is unoriented, entirely inked black. sectioned and submitted in its entirety. Summary of sections: SS - sequential sections. 10) The specimen is received fresh labeled "levels one and two left axillary. contents" It consists of a fragment of yellow adipose tissue measuring 12.5. x 10.5 x 2.8 cm. The levels are not designated. Numerous lymph nodes are. identified ranging in size from 0.4 cm up to 2.0 cm, and all are submitted. Summary: RLN-representative lymph node (multiple). ARLN-additional representative lymph nodes. LN-lymph nodes. Summary of Sections: Part 1: SP: Sentinel node #1 level one left axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. 1. rs. 1. Part 2: SP: Sentinel node #2 level one left axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. 1. rs. 1. Part 3: SP: Excision of tumor left breast two o'clock. Block. Sect. Site. PCs. 1. MT. 1. 1. SS. 1. 2. T. 2. Part 4: SP: Superior margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 5: SP: Medial margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 6: SP: Inferior margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 7: SP: Lateral margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 8: SP: Non-sentinel node left axilla. Block. Sect. Site. PCs. 1. bln. 1. Part 9: SP: Posterior margin left breast. Block. Sect. Site. PCs. 6. ss. 6. Part 10: SP: Levels one and two left axillary contents. Block. Sect. Site. PCs. 5. arln. 5. 5. LN. 12. 4. RLN. 4. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #1 level one left. axilla (fs) : Metastatic ductal carcinoma (1/1). PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #2 level one. left axilla (fs) Metastatic ductal carcinoma with extranodal extension. (1/1). PERMANENT DIAGNOSIS: SAME. Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #1 level one left. axilla (fs) : Metastatic ductal carcinoma (1/1). PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #2 level one. left axilla (fs) : Metastatic ductal carcinoma with extranodal extension. (1/1). PERMANENT DIAGNOSIS: SAME.

expanded version (tokens=3283) : 
 The breast pathology report describes the diagnosis of a LumA subtype, with a clinical diagnosis of 1.2 cm invasive duct carcinoma located on the upper outer quadrant of the left breast. The report provides a list of the specimens submitted, including sentinel nodes, margins of the breast tissue, levels of axillary contents, and non-neoplastic breast tissue.

The report describes the following:

- Histological classification: Invasive ductal carcinoma (NOS type) and ductal carcinoma in situ (DCIS), solid type with low to intermediate nuclear grade.
- Subtype: LumA subtype
- Description of necrosis: Focal vascular invasion is present.
- Tumor infiltrating lymphocytes: No information is provided about tumor infiltrating lymphocytes.
- Histological grade: Histologic grade II/III (moderate tubule formation).
- Nuclear grade: Nuclear grade I/III (slight or no variation in size and shape).
- Lymphovascular invasion: Focal vascular invasion is present.
- Calcification: Calcifications are present in the invasive carcinoma only.
- Receptor status: Estrogen receptor positive (ER 95% nuclear staining with intensity), progesterone receptor positive (PR 70% nuclear staining with moderate intensity), and HER2 negative (1+).
- IHC and ancillary testing results: The HER2 test was performed using an FDA-approved rabbit monoclonal primary antibody (clone 485) and shows negative results. The ER and PR rabbit

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=3449) : 
 The pathology report indicates a LumA subtype with 1.2 cm invasive ductal carcinoma and ductal carcinoma in situ (DCIS) with low to intermediate nuclear grade in the upper outer quadrant of the left breast. Focal vascular invasion is present, and calcifications are in invasive carcinoma only. Additionally, the tumor is estrogen receptor positive (ER 95%), progesterone receptor positive (PR 70%), and HER2 negative (1+). Histologic and nuclear grade are II/III and I/III, respectively. No information on tumor infiltrating lymphocytes was provided.

